



## PRESS RELEASE

For Immediate Release

### **PsychoGenics Achieves Milestone in its Discovery Collaboration with Roche**

TARRYTOWN, N.Y., November 16, 2011 – PsychoGenics Inc. today announced the achievement of a milestone in its drug discovery and development collaboration with Roche.

In May 2008, PsychoGenics and Roche entered into a drug discovery and development agreement to combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. PsychoGenics evaluated a library of Roche compounds, using its proprietary *in vivo* drug discovery technologies, leading to the discovery of a new drug candidate with the potential for a novel mode of action. Roche has decided to exercise its option to develop this drug candidate, thereby triggering a milestone payment to PsychoGenics.

PsychoGenics' technologies combine broad *in vivo* behavioral expertise with recent developments in robotics, computer vision, and bioinformatics to evaluate drug candidates for potential utility across the spectrum of Central Nervous System (CNS) disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds as well as early stage compounds including some with novel "first-in-class" mechanisms of action.

"We are pleased to have achieved this milestone which is further validation of PsychoGenics' phenotypic approach to CNS drug discovery. We have enjoyed an excellent working relationship with the talented Roche discovery team and look forward to supporting the development of this exciting program as well as other research programs." remarked Emer Leahy, Ph.D., PsychoGenics' President & Chief Executive Officer.

#### **About PsychoGenics**

PsychoGenics is a leader in *in vivo* phenotypic drug discovery. The Company applies its proprietary technology platforms in partnership with pharmaceutical and biotechnology companies to discover the next generation of drugs for neuropsychiatric disorders. PsychoGenics' capabilities also include standard behavioral testing, electrophysiology, molecular biology, and state of the art microdialysis. In addition, the company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington's disease, Autism spectrum disorders, psychosis/ schizophrenia, Parkinson's disease, Spinal Muscular Atrophy (SMA), Muscular dystrophy and other muscle disorders. For more information on PsychoGenics Inc. visit [www.psychogenics.com](http://www.psychogenics.com)

For more information contact:

Ms. Bavani Shankar

Vice President, Corporate Development

Ph: (914) 406-8060

[Bavani.Shankar@psychogenics.com](mailto:Bavani.Shankar@psychogenics.com)